Marijuana Toxicology Presentation
Marijuana usage is ubiquitous and growing, but not without consequences. Whatever your practice, marijuana may be involved.
View the presentation delivered at PACDL DUI & Motor Vehicle Summit on February 11, 2022 (PDF, 42 slides)
Legal brief addressing a ‘Not Guilty’ by reason of insanity in which psychiatric drug non-compliance was a factor
Compliance, or now more recently called adherence, is a topic well known to clinicians. Lack of taking medications results in the loss of any beneficial effects of any type of chronic (or even acute) drug therapy.
The topic was addressed in a recent murder trial in Cook County (Chicago, IL). For those of you who are health care professionals, this may interest you. For the lawyers, and do criminal (and possibly) civil law, the topic of compliance and adherence may be addressed in a variety of cases, not just murder cases.
Cannabis and Dentistry
Pharmaconsultant Partner, James J. O’Donnell PhD recently presented a seminar to the Lake County (IL) Dental (Society) on the topic of Marijuana: Considerations in Dental Practice. The PPT presentation provides a thorough review of marijuana pharmacology and toxicology information in general, and specific information relevant to Dentists. Anyone litigating (or using) marijuana may find this information useful and interesting. (PDF, 55 Slides)
Contrast Media Toxicity Case Reports
We have been consulted in numerous interesting cases that demonstrate that even drugs deemed generally safe for use can show serious side effects if certain factors go wrong.
If the drug dosing is incorrect, if the drug is not administered properly, if too much drug is given (overdose),
The Opioid Crisis and What Has Been Learned
The Opioid Epidemic dominated the news for several years; Covid 19 virus pandemic has quieted the news but not the epidemic. We published a short article on the history and lessons learned for your information. Pharmaconsultant experts have consulted and testified extensively in opiate toxicity cases.
Beyond Medical Cannabis: Considerations for Updates to Hospital Policies and Procedures
Cannabis (marijuana) is classified as a schedule-I controlled substance, currently not accepted for medical use and with a high potential for abuse. As stated in a previous P&T article, although marijuana remains illegal at the federal level, 33 states have legalized its medical use for certain indications and 10 have legalized its recreational use.
Among those states are differing laws that regulate the possession or supply of usable marijuana, with certain states providing more flexibility than others when it comes to using medical marijuana.
Regulatory and Legislative Disparities With Cannabis Present Challenges to P&T Committees and Health Care Providers
Over the past several years, the legal status of cannabis has been determined by regulatory changes affecting its use, as well as the use of cannabidiol (CBD). Prior to 2018, CBD, along with all forms of marijuana, was considered a Schedule I controlled substance (CI), indicating that these drugs had no medical use and presented a high potential for abuse. On June 25, 2018, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) for the treatment of Lennox-Gastaut and Dravet syndromes. Upon approval, …